Refinement R[F 2 > 2(F 2 )] = 0.029 wR(F 2 ) = 0.079 S = 1.10 2965 reflections 230 parameters H-atom parameters constrained Á max = 0.28 e Å À3 Á min = À0.19 e Å À3 Table 1 Hydrogen-bond geometry (Å , ). Symmetry codes: (i) Àx þ 1; Ày þ 1; Àz þ 1; (ii) Àx þ 1; Ày þ 2; Àz; (iii) x; y; z þ 1.
Data collection: CrysAlis PRO (Agilent, 2012); cell refinement: CrysAlis PRO; data reduction: CrysAlis PRO; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008) ; program(s) used to refine structure: SHELXL97 (Sheldrick, 2008) ; molecular graphics: Mercury (Macrae et al., 2006) and DIAMOND (Brandenburg, 2011) ; software used to prepare material for publication: publCIF (Westrip, 2010) .
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Radka Novotná and Zdeněk Trávníček Comment
The title compound (I) is derived from 6-benzylaminopurine, which is along with its derivatives classified among plant growth hormones called cytokinins, which influence crucial biochemical processes, such as cell cycle and division, in plant tissues. Suitable substitutions on the 6-benzylaminopurine skeleton, particularly in the C2 and N9 positions, lead to the formation of compounds that can act as inhibitors of enzymes cyclin dependent kinases in various phases of the human cell cycle (Meijer et al., 1997) . One representative of such derivatives, (R)-Roscovitine, i.e. 2-[(R)-(1-ethyl-2-hydroxyethylamino)]-6-(benzylamino)-9-isopropylpurine (Seliciclib or CYC202), has entered the IIb phase of clinical trials in patients with nonsmall cell lung cancer (Benson et al., 2005) . Moreover, 6-benzylaminopurine derivatives have been successfully used as N-donor ligands in transition metal complexes exhibiting varied types of biological activity. Even the title compound (I) has been employed as a ligand in the preparation of highly anticancer active platinum(II) oxalato complexes whose in vitro cytotoxic activity against various human cancer cells exceeded the commercially applied drug cisplatin (Štarha et al., 2010; Vrzal et al., 2010) .
The molecular structure of (I) consists of discrete molecules of a three-substituted adenine derivative, 2-chloro-6-[(2,4dimethoxybenzyl)amino]-9-isopropylpurine ( Fig. 1 ). It is basically derived from the 6-benzylaminopurine skeleton by substitutions of H atoms by the methoxy groups in the positions 2 and 4 on the benzene ring, by chlorine, and the isopropyl group in the position C2, and N9, of purine, respectively. The molecule contains two heterocyclic rings pyrimidine and imidazole, which are almost coplanar, since they form a dihedral angle of 2.02 (5)°. Additionally, there is also a benzene ring present in the structure of (I) which is similarly to the other two rings essentially planar. The maximum deviations from the least-square planes fitted through the non-hydrogen atoms for each of the rings are as follows: 0.0102 (14) Å for C4 in pyrimidine, 0.0025 (14) Å for C8 in imidazole and 0.007 (2) Å for C14 in benzene. The benzene and purine ring systems form a dihedral angle of 78.56 (4)°.
The crystal structure of (I) consists of the molecules of 2-chloro-6-[(2,4-dimethoxybenzyl)amino]-9-isopropylpurine organized into centrosymmetric dimers connected by N-H···N hydrogen bonds (Table 1 , Fig. 2 ). Additionally, varied types of non-covalent contacts are present in the structure of (I), namely C-H···O [d(C19···O2 iii ) = 3.471 (2) Å;
3.435 (2) Å], C-H···C [d(C17···C2 vi ) = 3.603 (2) Å; symmetry code: (vi) 2 -x, 1 -y, -z] as well as C···Cl contacts [d(C8···Cl1 vii ) = 3.3888 (11) Å; symmetry code: (vii) 1 -x, 2 -y, 1 -z] ( Fig. 3 and 4 ), forming an extended threedimensional network.
Experimental
Compound (I) was prepared, as a prospective ligand for syntheses of transition metal complexes, by the procedure described previously (Oh et al., 1999) . The resulting product was recrystallized from hot ethanol and crystals suitable for supplementary materials sup-2 Acta Cryst. (2013). E69, o390 X-ray analysis were formed after several days of slow evaporation at room temperature. The crystals were characterized by elemental analysis, NMR spectroscopy and single-crystal X-ray analysis. 1 
Refinement
Non-hydrogen atoms were refined anisotropically and hydrogen atoms were located in difference maps and refined using the riding model with C-H = 0.95 (CH), C-H = 0.99 (CH 2 ), C-H = 0.98 (CH 3 ) Å, and N-H = 0.88 Å, with U iso (H) = 1.2U eq (CH, CH 2 , NH) and 1.5U eq (CH 3 ).
Computing details
Data collection: CrysAlis PRO (Agilent, 2012); cell refinement: CrysAlis PRO (Agilent, 2012); data reduction: CrysAlis PRO (Agilent, 2012); program(s) used to solve structure: SHELXS97 (Sheldrick, 2008) ; program(s) used to refine structure: SHELXL97 (Sheldrick, 2008) ; molecular graphics: Mercury (Macrae et al., 2006) and DIAMOND (Brandenburg, 2011) ; software used to prepare material for publication: publCIF (Westrip, 2010) . A part of the crystal structure of (I) showing the present non-covalent interactions of the C-H···O, C-H···Cl, C-H···N, C-H···C types (symmetry codes: (i) 1 -x, 1 -y, 1 -z; (ii) 1 -x, 2 -y, -z; (iii) x, y, 1 + z; (iv) 1 -x, 1 -y, -z; (v) 2 -x, 2 -y, 1 -z; (vi) 2 -x, 1 -y, -z). Hydrogen atoms not involved in the contacts were omitted for clarity. Refinement. Refinement of F 2 against ALL reflections. The weighted R-factor wR and goodness of fit S are based on F 2 , conventional R-factors R are based on F, with F set to zero for negative F 2 . The threshold expression of F 2 > σ(F 2 ) is used only for calculating R-factors(gt) etc. and is not relevant to the choice of reflections for refinement. R-factors based on F 2 are statistically about twice as large as those based on F, and R-factors based on ALL data will be even larger.
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Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å 2 )
x y z U iso */U eq Cl1 0.70269 (5) 1.09303 (4) 0.25218 (2) 0.02037 (12) O1 0.32700 (14) 0.87203 (11) 0.09283 (7) 0.0211 (2) (7) 0.0141 (6) −0.0087 (5) −0.0062 (5) 0.0012 (5) C10 0.0178 (7) 0.0164 (7) 0.0153 (6) −0.0108 (5) −0.0054 (5) 0.0004 (5) C11 0.0153 (6) 0.0150 (6) 0.0182 (7) −0.0068 (5) −0.0049 (5) −0.0004 (5) C12 0.0206 (7) 0.0174 (7) 0.0146 (6) −0.0084 (6) −0.0058 (5) 0.0024 (5) supplementary materials sup-9
Acta Cryst. (2013). E69, o390 C13 0.0178 (7) 0.0190 (7) 0.0173 (7) −0.0098 (6) −0.0022 (5) −0.0032 (5) C14 0.0195 (7) 0.0131 (6) 0.0228 (7) −0.0045 (5) −0.0068 (6) −0.0012 (5) C15 0.0231 (7) 0.0163 (7) 0.0179 (7) −0.0098 (6) −0.0094 (6) 0.0031 (5) C16 0.0278 (8) 0.0227 (7) 0.0181 (7) 0.0001 (6) −0.0084 (6) 0.0033 (6) C17 0.0223 (7) 0.0218 (7) 0.0265 (8) −0.0052 (6) 0.0006 (6) −0.0071 (6) C18 0.0198 (7) 0.0155 (6) 0.0168 (7) −0.0091 (5) −0.0063 (5) −0.0012 (5) C19 0.0240 (7) 0.0232 (7) 0.0162 (7) −0.0114 (6) −0.0065 (6) −0.0013 (5) C20 0.0212 (8) 0.0354 (9) 0.0258 (8) −0.0124 (7) −0.0010 (6) −0.0129 (6) Geometric parameters (Å, º) 
